Itagil

Buspirone, the active ingredient in Itagil, is an azapirone anxiolytic presented as an oral tablet for oral use. It is indicated for the management of generalized anxiety disorder in adult patients, helping to reduce excessive worry and tension. It is absorbed after oral administration and reaches peak plasma concentrations within a few hours, offering a non‑sedating option for anxiety management.

GNH USA supplies Itagil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Buspirone acts on serotonergic pathways and is primarily used for anxiety disorders.

Generalized anxiety disorder: reduces excessive worry and tension in adult patients.

Buspirone may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Nausea: feeling of stomach upset or urge to vomit. - Nervousness: heightened sense of restlessness. - Insomnia: difficulty initiating or maintaining sleep. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood changes: emergence of depressive symptoms or suicidal thoughts. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Extrapyramidal symptoms: abnormal muscle movements or rigidity. - Hepatotoxicity: signs of liver injury such as jaundice.

Before initiating therapy, clinicians should consider several safety aspects. - Assess hepatic function: buspirone is metabolized in the liver, monitor in patients with liver disease. - Avoid abrupt discontinuation: taper the dose to prevent rebound anxiety. - Monitor mood: use caution in patients with a history of depression or suicidal ideation. - Avoid concomitant MAO inhibitors: risk of serotonin syndrome. - Pregnancy and lactation: limited data; prescribe only if potential benefit justifies potential risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Buspirone can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate serotonin syndrome. - SSRIs or SNRIs: increased risk of serotonin syndrome when combined.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise buspirone plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce buspirone effectiveness. - Alcohol: can enhance central nervous system depression and dizziness.